Meclizine Hydrochloride (meclizine hydrochloride 12.5 mg) Dailymed
Generic: meclizine hydrochloride
Go PRO for all pill images
Description
Meclizine hydrochloride, an oral antiemetic, is a white, slightly yellowish, crystalline powder which has a slight odor and is tasteless. It has the following structural formula:
C 25H 27CIN 2•2HCI•H 2O M.W. 481.89
The chemical name is 1-( p-chloro-alpha-phenylbenzyl)-4-( m-methyl-benzyl) - piperazine dihydrochloride monohydrate.
Meclizine Hydrochloride Tablets are available in 12.5 mg, and *25 mg strengths for oral administration.
*Contains FD&C Yellow #5 (see PRECAUTIONS).
Each tablet contains the following inactive ingredients: colloidal silicon dioxide, lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, starch, and stearic acid. In addition, the 12.5 mg tablet contains FD&C Blue #1; and the 25 mg tablet contains D&C Yellow #10 and FD&C Yellow #5.
Clinical Pharmacology
Meclizine hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.
Indications And Usage
For the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness.
Contraindications
Meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.
Warnings
Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.
Patients should avoid alcoholic beverages while taking the drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland. Do not give to children under 12 years of age unless directed by a doctor.
Precautions
The Meclizine Hydrochloride Tablets, 25 mg contain FD&C Yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow #5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
Usage in Children: Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended under 12 years of age.
Usage in Pregnancy: Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine hydrochloride increases the risk of abnormalities when administered during pregnancy.
Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine hydrochloride, or any other medication should be used during pregnancy only if clearly necessary.
Adverse Reactions
Drowsiness, dry mouth, and on rare occasions, blurred vision have been reported.
Dosage And Administration
Motion Sickness: The initial dose of 25 to 50 mg meclizine hydrochloride, should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.
How Supplied:
Meclizine Hydrochloride Tablets, USP 12.5 mg - blue, oval tablets debossed with “034” on one side and “par” on the other side. Tablets may contain characteristic dye spots. They are available as follows:
NDC 51079-089-20 - Unit dose buler packages of 100 (10 cards of 10 tablets each).
Meclizine Hydrochloride Tablets, USP 25 mg - yellow, oval tablets debossed with “035” on one side and “par” on the other side. They are available as follows:
NDC 51079-090-20 - Unit dose buler packages of 100 (10 cards of 10 tablets each).
Store at controlled room temperature 15° to 30°C (59° to 86°F).
Manufactured by: Par Pharmaceutical Companies, Inc. Spring Valley, NY 10977
Distributed by: UDL Laboratories, Inc. Rockford, IL 61103
S-5278 R13 3/10
Package Label.principal Display Panel
PRINCIPAL DISPLAY PANEL - 12.5 mg
NDC 51079-089-20
MECLIZINE HYDROCHLORIDE TABLETS, USP 12.5 mg
100 Tablets (10 x 10)
Each tablet contains: Meclizine HCl, USP . . . . . . 12.5 mg
USUAL DOSAGE: Read Accompanying Literature.
Store at controlled room temperature 15° to 30°C (59° to 86°F).
Manufactured by: Par Pharmaceutical Companies, Inc. Spring Valley, NY 10977
Rx only
S-5276 R7
Packaged and Distributed by:
UDL LABORATORIES, INC.
ROCKFORD, IL 61103
This unit dose package is not child resistant.
For institutional use only.
Keep this and all drugs out of the reach of children.
This container provides light-resistance.
See window for lot number and expiration date.
Package Label.principal Display Panel
PRINCIPAL DISPLAY PANEL - 25 mg
NDC 51079-090-20
MECLIZINE HYDROCHLORIDE TABLETS, USP 25 mg
100 Tablets (10 x 10)
Each tablet contains: Meclizine HCl, USP . . . . . . 25 mg
USUAL DOSAGE: Read Accompanying Literature.
CAUTION: This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic type reactions in certain susceptible individuals.
Store at controlled room temperature 15° to 30°C (59° to 86°F).
Manufactured by: Par Pharmaceutical Companies, Inc. Spring Valley, NY 10977
Rx only
S-5277 R7
Packaged and Distributed by:
UDL LABORATORIES, INC.
ROCKFORD, IL 61103
This unit dose package is not child resistant.
For institutional use only.
Keep this and all drugs out of the reach of children.
This container provides light-resistance.
See window for lot number and expiration date.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site